Antioxidant therapy for chronic hepatitis C
Clinical laboratory studies were made in 47 patients with chronic hepatitis C (CHC). The comprehensive studies involved the evaluation of a number of oxidative metabolic parameters, antioxidant enzymes, and nitric oxide metabolism products. All the studies were performed in the course of the disease. The basic therapy of 30 patients with CHC included ceruloplasmin; 17 patients made up a comparison group. The proposed antioxidant therapy with ceruloplasmin was found to have not only a positive impact on the clinical course of CHC, but also to affect redox homeostasis and the levels of azotoxidemia in the examinees.